Principal Financial Group Inc Supernus Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

A detailed history of Principal Financial Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 285,411 shares of SUPN stock, worth $10.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

285,411

Previous 270,845 5.38%

Holding current value

$10.3 Million

Previous $7.25 Million 22.83%

% of portfolio

0.01%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$25.77 - $35.16 $375,365 - $512,140	14,566 Added 5.38%	285,411 $8.9 Million
Q2 2024 Jul 29, 2024	SELL	$25.99 - $33.85 $341,794 - $445,161	-13,151 Reduced 4.63%	270,845 $7.25 Million
Q1 2024 Apr 29, 2024	SELL	$27.11 - $35.17 $445,878 - $578,440	-16,447 Reduced 5.47%	283,996 $9.69 Million
Q4 2023 Feb 07, 2024	SELL	$22.72 - $29.68 $75,816 - $99,042	-3,337 Reduced 1.1%	300,443 $8.69 Million
Q3 2023 Nov 02, 2023	SELL	$27.57 - $32.91 $380,907 - $454,684	-13,816 Reduced 4.35%	303,780 $8.38 Million
Q2 2023 Aug 07, 2023	SELL	$29.91 - $38.73 $503,534 - $652,019	-16,835 Reduced 5.03%	317,596 $9.55 Million
Q1 2023 May 09, 2023	SELL	$34.93 - $42.03 $181,810 - $218,766	-5,205 Reduced 1.53%	334,431 $12.1 Million
Q4 2022 Feb 09, 2023	SELL	$31.09 - $37.88 $100,234 - $122,125	-3,224 Reduced 0.94%	339,636 $12.1 Million
Q3 2022 Nov 09, 2022	SELL	$28.79 - $35.41 $677,457 - $833,232	-23,531 Reduced 6.42%	342,860 $11.6 Million
Q2 2022 Aug 10, 2022	SELL	$25.33 - $34.25 $719,498 - $972,871	-28,405 Reduced 7.19%	366,391 $10.6 Million
Q1 2022 May 09, 2022	SELL	$28.51 - $32.9 $611,767 - $705,968	-21,458 Reduced 5.16%	394,796 $12.8 Million
Q4 2021 Feb 09, 2022	SELL	$26.37 - $34.22 $1 Million - $1.3 Million	-38,102 Reduced 8.39%	416,254 $12.1 Million
Q3 2021 Nov 09, 2021	BUY	$23.54 - $31.39 $17,490 - $23,322	743 Added 0.16%	454,356 $12.1 Million
Q2 2021 Aug 10, 2021	BUY	$26.72 - $33.19 $620,759 - $771,070	23,232 Added 5.4%	453,613 $14 Million
Q1 2021 May 10, 2021	BUY	$24.15 - $31.45 $154,535 - $201,248	6,399 Added 1.51%	430,381 $11.3 Million
Q4 2020 Feb 08, 2021	BUY	$17.7 - $25.81 $799,880 - $1.17 Million	45,191 Added 11.93%	423,982 $10.7 Million
Q3 2020 Nov 06, 2020	SELL	$20.2 - $25.05 $317,382 - $393,585	-15,712 Reduced 3.98%	378,791 $7.89 Million
Q2 2020 Aug 05, 2020	SELL	$17.09 - $24.89 $69,351 - $101,003	-4,058 Reduced 1.02%	394,503 $9.37 Million
Q1 2020 May 12, 2020	SELL	$14.45 - $24.69 $254,276 - $434,469	-17,597 Reduced 4.23%	398,561 $7.17 Million
Q4 2019 Feb 05, 2020	SELL	$19.93 - $29.13 $667,435 - $975,534	-33,489 Reduced 7.45%	416,158 $9.87 Million
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $110,718 - $145,059	4,347 Added 0.98%	449,647 $12.4 Million
Q2 2019 Aug 12, 2019	SELL	$29.96 - $38.87 $508,720 - $660,012	-16,980 Reduced 3.67%	445,300 $14.7 Million
Q1 2019 May 10, 2019	SELL	$32.77 - $41.99 $78,680 - $100,817	-2,401 Reduced 0.52%	462,280 $16.2 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $372,670 - $598,278	12,084 Added 2.67%	464,681 $15.4 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $876,631 - $1.16 Million	20,530 Added 4.75%	452,597 $22.8 Million
Q2 2018 Aug 13, 2018	BUY	$44.1 - $59.85 $397,120 - $538,949	9,005 Added 2.13%	432,067 $0
Q1 2018 May 14, 2018	BUY	$37.15 - $46.9 $491,791 - $620,862	13,238 Added 3.23%	423,062 $19.4 Million
Q4 2017 Feb 13, 2018	BUY	$36.4 - $42.6 $110,983 - $129,887	3,049 Added 0.75%	409,824 $16.3 Million
Q3 2017 Nov 02, 2017	BUY	$36.75 - $49.65 $14.9 Million - $20.2 Million	406,775	406,775 $16.3 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Supernus Pharmaceuticals, Inc. Transaction History